Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1994 Oct;120(10):593–598. doi: 10.1007/BF01212813

Reduced oxygenation in a rat mammary carcinoma after chemo- or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing

Beverly A Teicher 1,✉, Enrique Alvarez Sotomayor 1, Norman P Dupuis 1, Tetsuya Kusumoto 1, Krishna Menon 1
PMCID: PMC12201892  PMID: 7929530

Abstract

Rat 13672 mammary carcinoma tumors were grown subcutaneously in the hind legs of female Fischer 344 rats to a volume of about 1 cm3. Tumor oxygenation was measured using an EppendorfPO2 histograph. Tumor oxygen measurements were made under four conditions: (a) normal air breathing, (b) carbogen breathing, (c) after intravenous administration of a perflubron emulsion (8 ml/kg) with air breathing and (d) after intravenous administration of a perflubron emulsion (8 ml/kg) with carbogen breathing. Tumor oxygenation was examined without treatment or 24 h and 48 h after treatment with cyclophosphamide (300 mg/kg, i.p.) or cisplatin (8 mg/kg, i.p.] or after the fifth dose of a daily regimen of 3-Gy irradiation (5×3 Gy). Under normal air-breathing conditions 49% of the tumor had aPO2≤670 Pa (5 mm Hg). The degree of hypoxia in the tumors increased after each treatment such that 24 h after treatment 65%–85% of the oxygen readings were ≤670 Pa and 48 h after treatment 60%–74% of the oxygen readings were ≤670 Pa. Administration of the perflubron emulsion/carbogen atmosphere increased the oxygen content of the tumors both without treatment and after each of the treatments. A knowledge of tumor oxygen content over the course of treatment and the ability to increase tumor oxygen should allow for the development of more rational treatment combinations and better treatment outcomes.

Key words: Post-chemotherapy reoxygenation, Post-radiation therapy oxygenation, Perflubron emulsion/carbogen breathing

Footnotes

This work was supported by NIH grant P01-Ca19589 and a grant from Alliance Pharmaceutical Corporation, San Diego, Calif. This work was presented in part at the Chemical Modifiers of Cancer Treatment meeting, June 1993, in Kyoto, Japan

References

  1. Dorie MJ, Kallman RF (1986) Reoxygenation of the RIF-1 tumor after fractionated radiotherapy. Int J Radiat Oncol Biol Phys 12:1853–1859 [DOI] [PubMed] [Google Scholar]
  2. Evans RG, Kimler BF, Morantz RA, Vats TS, Gemer LS, Liston V, Lowe N (1990) A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys 19:415–420 [DOI] [PubMed] [Google Scholar]
  3. Evans RG, Kimler BF, Morantz RA, Batnitzky S (1993) Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors. Int J Radiat Oncol Biol Phys 26:649–652 [DOI] [PubMed] [Google Scholar]
  4. Garewal H, Skarin A, Kessler J, Smith R, Hedberg J (1989) Fluosol/oxygen in combination with cyclophosphamide in advanced non-small cell lung carcinoma (NSCLC): Phase I results. Proc Am Assoc Cancer Res 30:271 [Google Scholar]
  5. Grau C, Overgaard J (1990) The influence of radiation dose on the magnitude and kinetics of reoxygenation in a C3H mammary carcinoma. Radiat Res 122:309–315 [PubMed] [Google Scholar]
  6. Gruber M, Prados M, Russell C, Hochberg F, Cook P, Weissman D, Evans R, Burton G, Allen D, Brannon R (1990) Phase I/II study of Fluosol/O2 in combination with BCNU in malignant glioma. Proc Am Assoc Cancer Res 31:190 [Google Scholar]
  7. Howes AE, Page A, Fowler JF (1972) The effects of single and fractionated doses of x-rays on the effective proportion of hypoxic cells in C3H mouse mammary tumors. Br J Radiol 45:250–256 [DOI] [PubMed] [Google Scholar]
  8. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48:2641–2658 [PubMed] [Google Scholar]
  9. Kallman RF (1988) Reoxygenation and repopulation in irradiated tumors. Front Radiat Ther Oncol 22:30–49 [DOI] [PubMed] [Google Scholar]
  10. Kallman RF, Jardine LJ, Johnson CW (1970) Effects of different schedules of dose fractionation on the oxygenation status of a transplantable mouse sarcoma. J Natl Cancer Inst 44:369–377 [PubMed] [Google Scholar]
  11. Lustig R, McIntosh-Lowe N, Rose C, Haas J, Krasnow S, Spaulding M, Prosnitz L (1989) Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 16:1587–1593 [DOI] [PubMed] [Google Scholar]
  12. Lustig R, Lowe N, Prosnitz L, Spaulding M, Cohen M, Stitt J, Brannen R (1990) Phase I/II study of Fluosol-DA and 100% oxygen breathing as an adjuvant to radiation in the treatment of unresectable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 19:97–102 [DOI] [PubMed] [Google Scholar]
  13. Meyers F, Alberts D, Spaulding M, Garewal H, Flam M, Allen D (1989) Phase I/II study of Fluosol/oxygen in combination with weekly 5-fluorouracil (5FU) in metastatic colorectal carcinoma. Proc Am Assoc Cancer Res 30:256 [Google Scholar]
  14. Riess JG (1984) Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs 8:44–56 [DOI] [PubMed] [Google Scholar]
  15. Rose C, Lustig R, McIntosh N, Teicher BA (1986) A clinical trial of Fluosol-DA in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 12:1325–1327 [DOI] [PubMed] [Google Scholar]
  16. Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfusedex vivo: effects of tumor size and perfusion pressure. Cancer Res 49:3513–3519 [PubMed] [Google Scholar]
  17. Teicher BA, Holden SA (1987) A survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents. Cancer Treat Rep 71:173–177 [PubMed] [Google Scholar]
  18. Teicher BA, Holden SA, Rose CM (1985) Differential enhancement of melphalan cytoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing. Int J Cancer 36:585–589 [DOI] [PubMed] [Google Scholar]
  19. Teicher BA, Crawford JM, Holden SA, Cathcart KNS (1987) Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res 47:5036–5041 [PubMed] [Google Scholar]
  20. Teicher BA, Holden SA, Jacobs JL (1987) Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47:513–518 [PubMed] [Google Scholar]
  21. Teicher BA, Herman TS, Holden SA, Cathcart KNS (1988a) The effect of Fluosol-DA and oxygenation status on the activity of cyclo phosphamidein vivo. Cancer Chemother Pharmacol 21:286–291 [DOI] [PubMed] [Google Scholar]
  22. Teicher BA, Herman TS, Rose CM (1988b) Effect of Fluosol-DA on the response of intracranial 9L tumors to x-rays and BCNU. Int J Radiat Oncol Biol Phys 15:1187–1192 [DOI] [PubMed] [Google Scholar]
  23. Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulationsin vivo in FSallC murine fibrosarcoma. Cancer Res 50:3339–3344 [PubMed] [Google Scholar]
  24. Teicher BA, Holden SA, Rose CM (1986) Effect of Fluosol-DA/O2 on tumor cell and bone marrow cytotoxicity of nitrosoureas in mice bearing FSall fibrosarcoma. Int J Cancer 38:285–288 [DOI] [PubMed] [Google Scholar]
  25. Teicher BA, Lazo JS, Sartorelli AC (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73–81 [PubMed] [Google Scholar]
  26. Teicher BA, McIntosh-Lowe NL, Rose CM (1988) Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents. Biomater Artif Cells Immunobiol Biotechnol 16:533–546 [DOI] [PubMed] [Google Scholar]
  27. Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E (1989) Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity ofN,N′,N′-triethylenethiophosphoramide. Cancer Res 49:4996–5001 [PubMed] [Google Scholar]
  28. Thomlinson RH (1968) Changes of oxygenation in relation to irradiation. Front Radiat Ther Oncol 3:109–121 [Google Scholar]
  29. Van Putten LM (1968) Tumor reoxygenation during fractionated radiotherapy: studies with transplantable mouse osteosarcoma. Eur J Cancer 4:173–182 [DOI] [PubMed] [Google Scholar]
  30. Van Putten LM, Kallman RF (1982) Oxygenation status of a transplantable tumor during fractionated radiation therapy. J Natl Cancer Inst 40:441–451 [PubMed] [Google Scholar]
  31. Vaupel PW (1993) Oxygenation of solid tumors. In: Teicher B (ed) Drug resistance in oncology. Dekker, New York, pp 53–87 [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES